| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
AstraZeneca |
| Information provided by: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00524251 |
Purpose
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)
| Condition | Intervention |
|
GERD Quality of Life |
Drug: esomeprazole |
| ChemIDplus related topics: | Esomeprazole magnesium Esomeprazole Sodium Omeprazole Omeprazole magnesium |
| Study Type: | Observational |
| Study Design: | Prospective |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations |
Show 54 Study Locations |
| AstraZeneca |
| Study Director: | A Sellink, MD | AstraZeneca |
| Study Chair: | N van den Berk | AstraZeneca |
More Information
Related Info
|
| Study ID Numbers: | N11 |
| First Received: | August 29, 2007 |
| Last Updated: | September 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00524251 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
|
|
|
|
